MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "NMDA"

  • 2023 International Congress

    24(S)-Hydroxycholesterol and cognition in Huntington’s disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)

    S. Gray, M. Lewis, T. Kazdoba, A. Koenig, E. Lefler, K. Paumier, M. Quirk, J. Doherty (Cambridge, USA)

    Objective: To investigate correlations between plasma levels of 24(S)-Hydroxycholesterol (24[S]-HC) and cognitive performance in participants with Huntington’s disease (HD) using data from ENROLL-HD. Background: HD…
  • 2023 International Congress

    Glunomab: a novel therapeutics for the treatment of Parkinson’s Disease

    D. Torrente, E. Su, GP. Schielke, M. Warnock, T. Stevenson, K. Mann, F. Lesept, N. Delétage, M. Blanc, D. Vivien, D. Lawrence (Ann Arbor, USA)

    Objective: The focus of this study was: 1) to characterize the expression and the localization of an endogenous protease, tissue plasminogen activator (tPA) in the…
  • 2022 International Congress

    GRIN2D is a cause of autosomal dominant form of Parkinson’s disease

    A. Kishore, M. Sturm, J. Shin, S. Grover, F. Raimondi, C. Blauwendraat, S. Robert, G. Sarma, N. Casadei, P. Lichtner, A. Kumar-Sreelatha, J. Winkelmann, R. Krüger, A. Singleton, T. Gasser, P. Seth, J. Roeper, O. Riess, M. Sharma (Kochi, India)

    Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…
  • 2022 International Congress

    Isolated craniocervical dystonia without neuropsychiatric manifestations associated with NMDA-receptor antibodies

    S. Waller, L. Williams, A. Lee, MW. Lin, H. Morales-Briceno, V. Fung (Westmead, Australia)

    Objective: N-methyl-D-aspartate receptor (NMDAR) encephalitis classically spans neuropsychiatric disturbance, autonomic dysfunction and salient movement disorders. Attenuated presentations are increasingly recognised; however, presentations with an isolated…
  • 2022 International Congress

    Movement disorders in pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis

    M. Jamoussi, H. Benrhouma, Z. Miladi, T. Ben Younes, H. Klaa, I. Kraoua, I. Ben Youssef, M. Ben Ahmed (Tunis, Tunisia)

    Objective: Our aim was to investigate clinical characteristics and evolution of movement disorders (MD) in pediatric anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Background: Movement disorders account for…
  • 2022 International Congress

    Combined anti N-Methyl-D- Aspartate receptor (NMDAR) encephalitis with autoimmune thyroiditis (AT), with good clinical recovery.

    M. Farghal, M. Abu Hashish (Ahmadi, Kuwait)

    Objective: To report anti NMDAR encephalitis patient, with evidence of AT, and to explain her clinical presentation, management and outcome. Background: Autoimmune encephalitis(AE) is nowadays…
  • MDS Virtual Congress 2021

    NMDA Receptor Antibodies and Neuropsychiatric Symptoms in Parkinson’s Disease

    L. Gibson, T. Pollak, M. Hart, D. Trivedi, T. Nicholson, M. Zandi, K R. Chaudhuri, D. Aarsland (London, United Kingdom)

    Objective: To quantify the frequency of NMDA receptor (NMDAR) antibodies (Abs) in Parkinson’s disease (PD) and characterise their relationship with the cognitive and neuropsychiatric symptoms.…
  • MDS Virtual Congress 2020

    4-Chlorokynurenine inhibits L-Dopa-induced dyskinesias in non-human parkinsonian primates

    T. Di Paolo, M. Bourque, R. Snodgrass (Quebec City, QC, Canada)

    Objective: This study investigated the antidyskinetic activity of 4-chlorokynurenine (AV-101) in parkinsonian monkeys with L-Dopa-induced dyskinesias. Background: The common treatment for Parkinson’s disease (PD) is L-Dopa…
  • MDS Virtual Congress 2020

    Movement disorders and it association with immunological causes: the key is in the movement

    E.M Gatto, G. Da Prat, J.L Etcheverry, M.E Cesarini, N. Gonzalez Rojas (CABA, Argentina)

    Objective: Observe the clinical and biochemical characteristics and the result of the treatment instituted in movement immune-mediated etiology. Background: Paraneoplastic autoimmune movement disorders are a…
  • 2019 International Congress

    Rapidly progressive cognitive decline and hemi-dystonia due to anti-neuronal surface antibodies

    F. Rolim, L. Mendes, P. Braga Neto, R. Sampaio, G. Ferreira, P. Nóbrega, V. Mesquita, F. Maia (Fortaleza, Brazil)

    Objective: To describe a case of marked asymmetric coarse tremor and dystonia in patient diagnosed with anti-NMDAR encephalitis. Background: Anti-NMDAR encephalitis has complex and heterogeneous…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley